<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522102</url>
  </required_header>
  <id_info>
    <org_study_id>ASPIRING</org_study_id>
    <nct_id>NCT04522102</nct_id>
  </id_info>
  <brief_title>Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase</brief_title>
  <official_title>An Investigator Initiated and Conducted, Prospective, Multicentre, Randomised Outcome-blinded Pilot Study of Antiplatelet Therapy in Patients With a History of Stroke Due to Intracerebral Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute for Global Health, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute for Global Health, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind&#xD;
      outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility&#xD;
      of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet&#xD;
      therapy for reducing all serious vascular events for adults surviving symptomatic stroke due&#xD;
      to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve ~120 patients at&#xD;
      ~30 hospitals in China, Australia and New Zealand.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participant eligibility criteria specifically identify adults with history of symptomatic&#xD;
      spontaneous ICH. Randomisation occurs if a participant and their doctor are uncertain about&#xD;
      whether to start or avoid antiplatelet monotherapy at least 24 hours after ICH symptom onset.&#xD;
      The intervention is a pragmatic policy of starting antiplatelet monotherapy (one antiplatelet&#xD;
      drug available in local standard clinical practice, chosen by patient's physician&#xD;
      pre-randomisation). The control group adopts a policy of avoiding antiplatelet therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 3, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>regulatory approvals</measure>
    <time_frame>6 months</time_frame>
    <description>Receipt of regulatory approvals in China，Australia and New Zealand separately, including Ethics, Human Genetics Resources Administration of China (HGRAC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>trial database</measure>
    <time_frame>6 months</time_frame>
    <description>Trial database structure and data flows that comply with data privacy and information governance regulations in China, Australia and New Zealand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site recruitment</measure>
    <time_frame>12-18 month</time_frame>
    <description>Participation of 20 sites in China and 10 sites in Australia and New Zealand</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate frequency of clinical data</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of ICH survivors who are screened, eligible, approached, consented, and randomised by month and site from activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barriers to randomisation of eligible patients.</measure>
    <time_frame>3 years</time_frame>
    <description>Barriers to randomisation of eligible patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of protocol deviations and violations.</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of protocol deviations and violations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the allocated intervention by investigators and participants</measure>
    <time_frame>3 years</time_frame>
    <description>Adherence to the allocated intervention by investigators and participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of withdrawal and loss to follow-up</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of withdrawal and loss to follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completeness of follow-up assessments</measure>
    <time_frame>3 years</time_frame>
    <description>Completeness of follow-up assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of randomised participants compared with eligible patients who were not recruited.</measure>
    <time_frame>3 years</time_frame>
    <description>Characteristics of randomised participants compared with eligible patients who were not recruited.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of the composite of all serious vascular events</measure>
    <time_frame>6 months</time_frame>
    <description>composite of all serious vascular events (non-fatal stroke, non-fatal myocardial infarction or death from a vascular cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event (SAE)</measure>
    <time_frame>at least 6 months</time_frame>
    <description>any serious adverse event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse reaction (SAR)</measure>
    <time_frame>at least 6 months</time_frame>
    <description>serious adverse reaction (SAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suspected Unexpected Serious Adverse Reaction (SUSAR)</measure>
    <time_frame>at least 6 months</time_frame>
    <description>Suspected Unexpected Serious Adverse Reaction (SUSAR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Avoid antiplatelet therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Start antiplatelet monotherapy</intervention_name>
    <description>Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age ≥18 years.&#xD;
&#xD;
          2. Symptomatic stroke due to spontaneous (non-traumatic) ICH.&#xD;
&#xD;
          3. Patient is at least 24 hours after ICH symptom onset.&#xD;
&#xD;
          4. Patient and their doctor are both uncertain about whether to start or avoid&#xD;
             antiplatelet monotherapy.&#xD;
&#xD;
          5. Consent to randomisation from the patient (or personal / legal / professional&#xD;
             representative if the patient does not have mental capacity).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ICH due to head injury, in the opinion of the investigator.&#xD;
&#xD;
          2. ICH due to haemorrhagic transformation of an ischaemic stroke, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          3. Patient is already taking antiplatelet therapy, or full dose anticoagulant therapy,&#xD;
             after ICH.&#xD;
&#xD;
          4. Patient is pregnant, breastfeeding, or of childbearing age and not taking&#xD;
             contraception.&#xD;
&#xD;
          5. Patient and carer unable to understand spoken or written local language.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rustam Al-Shahi Salman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig S Anderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Graeme Hankey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rustam AI-Shahi Salman</last_name>
    <phone>+44 131 242 7014</phone>
    <email>Rustam.Al-Shahi@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lily Song</last_name>
    <phone>+86 13916466400</phone>
    <email>lsong@georgeinstitute.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lily Song</last_name>
      <phone>+86 13916466400</phone>
      <email>lsong@georgeinstitute.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chen Chen</last_name>
      <phone>+86 15921119641</phone>
      <email>cchen1@georgeinstitute.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Cheng</last_name>
      <phone>13917274123</phone>
      <email>chengxin@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>cilostazol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

